Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-24T02:21:40.064Z Has data issue: false hasContentIssue false

13 - Complications of Cirrhosis

Published online by Cambridge University Press:  08 August 2009

By
Jorge L. Herrera
Edited by
Zobair M. Younossi
Zobair M. Younossi
Affiliation:
Inova Fairfax Hospital, Annandale, VA
Get access

Summary

BACKGROUND

Chronic liver disease is one of the leading causes of death in the United States. As a result of the hepatitis C virus (HCV) epidemic 20–30 years ago, it is expected that by 2020 the proportion of chronic HCV patients with cirrhosis will double from 16% to 32%, and there will be a 180% increase in liver-related deaths. Although only liver transplantation is able to reverse the complications of advanced liver disease, the number of patients awaiting orthotopic liver transplantation has grown to 17,562 as of November 2006. Many patients with cirrhosis are not eligible for liver transplantation or may not receive an organ transplant during their lifetime.

Most patients with chronic liver disease receive their medical care from primary care physicians or gastroenterologists. A clear understanding of the pathophysiology of chronic liver disease, its possible complications, and management are important to deliver state of the art care to patients with chronic liver disease.

PROGNOSIS OF CIRRHOSIS

Most chronic liver diseases generally run a steady course with gradual deterioration over time. The natural history of cirrhosis is characterized by an asymptomatic phase, also known as “compensated cirrhosis,” followed by a rapidly progressive phase marked by the development of complications of portal hypertension and/or liver dysfunction, termed “decompensated cirrhosis.” Transition from a compensated to a decompensated stage occurs at a rate of approximately 5–7% per year. The development of decompensation is an important milestone in the natural history of cirrhosis.

Type
Chapter
Information
Practical Management of Liver Diseases , pp. 215 - 234
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kochanek, KD, Murphy, SL, Anderson, RN. Deaths: Final data for 2002. In National Center for Health Statistics. National Vital Statistics Report. Vol 53, No. 5, Hyatsville, MD. National Center for Health Statistics 2004.
Davis, GL, Albright, JE, Cook, SF, Rosenberg, DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331–8.CrossRefGoogle ScholarPubMed
,United Network for Organ Sharing and Organ Procurement and Transplant Network, Richmond, VA. Current U.S. waiting list for liver transplantation. In: United Network for Organ Sharing; 2006. Available at http://www.unos.org/data. Accessed on November 26, 2006.
D'Amico, G, Garcia-Tsao, G, Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006;44:217–31.CrossRefGoogle ScholarPubMed
Fattovich, G, Giustina, G, Degos, F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–72.CrossRefGoogle ScholarPubMed
Alberti, A, Chemelo, L, Benvegnu, L. Natural history of hepatitis C. J Hepatol 1999;31(Suppl. 1):17–24.CrossRefGoogle Scholar
Christensen, E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores – Where are we and where should we go?J Hepatol 2004;41:344–50.CrossRefGoogle Scholar
Pugh, RN, Murray-Lyon, IM, Dawson, JL, Peitroni, MC, Williams, R. Transection of the esophagus for bleeding esophageal varices. Br J Surg 1973;60:646–49.CrossRefGoogle Scholar
Kamath, PS, Wiesner, RH, Malinchoc, M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–70.CrossRefGoogle ScholarPubMed
Gores, GJ, Wiesner, RH, Dickson, ER, Zinsmeister, AR, Jorgensen, RA, Langworthy, A. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history and influence on survival. Gastroenterology 1989;96:1552–9.CrossRefGoogle ScholarPubMed
Kamath, PS. Esophageal variceal bleeding: Primary prophylaxis. Clinical Gastroenterol Hepatology 2005;3:90–3.CrossRefGoogle ScholarPubMed
Thuluvath, PJ, Kirshnan, A. Primary prophylaxis of variceal bleeding. Gastrointest Endosc 2003;58:558–67.CrossRefGoogle ScholarPubMed
D'Amico, G, Pagliaro, L, Bosch, J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332–54.CrossRefGoogle ScholarPubMed
Poynard, T, Cales, P, Pasta, L, Ideo, G, Pascal, JP, Pagliaro, L, Lebrec, D. Beta-adrenergic antagonists in the prevention of first gastrointestinal bleeding in patiens with cirrhosis and esophageal varices. Analysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Engl J Med 1991;324:1532–38.CrossRefGoogle Scholar
Plevris, JN, Elliot, R, Mills, PR, Hislop, WS, Davies, JM, Bouchier, IA, Hayes, PC. Effect of propranolol on prevention of first variceal bleed and survival in patients with chronic liver disease. Aliment Pharmacol Ther 1994;8:63–70.CrossRefGoogle ScholarPubMed
Groszmann, RJ, Garcia-Tsao, G, Bosch, J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254–61.CrossRefGoogle ScholarPubMed
Beppu, K, Inokuchi, K, Koyanagi, N, Nakayama, S, Sakata, H, Kitano, S, et al. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc 1981;27: 213–8.CrossRefGoogle ScholarPubMed
Adams, PC, Arthur, MJ, Boyer, TD, DeLeve, LD, Di Bisceglie, AM, Hall, M, et al. Screening in liver disease: Report of an AASLD workshop. Hepatology 2004;39:1204–12.CrossRefGoogle ScholarPubMed
Grace, ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 1997;92:1081–91.Google ScholarPubMed
,ASGE. ASGE Guideline: the role of endoscopy in the management of variceal hemorrhage, updated July 2005. Gastointest Endosc 2005;62:651–55.CrossRefGoogle Scholar
D'Amico, G, Pasta, L, Madonia, S, Tarantino, G, Mancuso, A, Malizia, G, Giannuoli, GC, Pagliaro, L. The incidence of esophageal varices in cirrhosisGastroenterology 2001;120:A-2 (abstract).CrossRefGoogle Scholar
Bosch, J, Abraldes, JG, Groszmann, R. Current management of portal hypertension. J Hepatol 2003;38:554–68.CrossRefGoogle ScholarPubMed
Abraczinskas, DR, Ookubo, R, Grace, ND, Groszmann, RJ, Bosch, J, Garcia-Tsao, G, et al. Propranolol for prevention of first esophageal variceal hemorrhage – A lifetime commitment?Hepatology 2001;34:1096–102.CrossRefGoogle ScholarPubMed
Jensen, DM. Endoscopic screening for varices in cirrhosis: Findings, implications and outcomes. Gastroenterology 2002;122:1620–30.CrossRefGoogle ScholarPubMed
Carbonell, N, Pauwels, A, Serfaty, L, et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004;40:652–9.CrossRefGoogle ScholarPubMed
Ejlersen, E, Melsen, T, Ingerslev, J, et al. Recombinant activated factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 2001;36:1081–5.Google Scholar
Bernard, B, Grange, JD, Khac, EN, Amiot, X, Opolon, P, Poynard, T. Antibiotic prophylaxis for the prevention of bacterial infection in cirrhotic patients with gastrointestinal bleeding: a meta–analysis. Heptology 1999;29:1655–61.CrossRefGoogle ScholarPubMed
Garica-Tsao, G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol 2005;S85–92.CrossRefGoogle Scholar
Corley, DA, Cello, JP, Adkisson, W, et al. Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology 2001;120:946–54.CrossRefGoogle ScholarPubMed
Bosch, J, Lebrec, D, Jenkis, SA. Development of analogues: successes and failures. Scand J Gastroenterol Suppl 1998;226:3–13.CrossRefGoogle ScholarPubMed
Lo, GH, Lai, KH, Cheng, JS, Lin, CK, Huang, JS, Hsu, PL, et al. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology 1997;25:1101–4.CrossRefGoogle ScholarPubMed
D'Amico, G, Pagliaro, L, Bosch, J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332–54.CrossRefGoogle ScholarPubMed
Garcia-Tsao, G. Current management of the complications of cirrhosis and portal hypetension: Variceal hemorrhage, ascites and spontaneous bacterial peritonitis. Gastroenterology 2001;120:726–48.CrossRefGoogle Scholar
D'Amico, G, Plagiaro, L, Bosch, J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liv Dis 1999;19:475–505.CrossRefGoogle Scholar
Patch, D, Sabin, CA, Goulis, J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002;123:1013–19.CrossRefGoogle ScholarPubMed
de la Peña, J, Brullet, E, Sanchez-Hernandez, E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005;41:572–8.CrossRefGoogle ScholarPubMed
Abraldes, JG, Angermayr, B, Bosch, J. The management of portal hypertension. N A Clin Liv Dis 2005;9:685–713.CrossRefGoogle ScholarPubMed
Lo, GH, Lai, KH, Cheng, JS, et al. A prospective randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 2001;33:1060–4.CrossRefGoogle ScholarPubMed
Gines, P, Quintero, E, Arroyo, V, Teres, J, Bruguera, M, Rimola, A, Caballeria, J, et al. Com- pensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:12–18.CrossRefGoogle Scholar
Schrier, RW, Arroyo, V, Bernaqrdi, M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151–7.CrossRefGoogle ScholarPubMed
Runyon, BA. Care of the patient with ascites. N Engl J Med 1994;330:337–42.CrossRefGoogle Scholar
Pinzello, G, Simonetty, RG, Craxi, A, di Piazza, S, Spano, C, Pagliaro, L. Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic patients. Hepatology 1983;3:545–9.Google Scholar
Runyon, BA. Paracentesis of ascitic fluid: a safe procedure. Arch Intern Med 1986; 146:2259–61.CrossRefGoogle ScholarPubMed
Lin, CH, Shih, FY, Ma, MH, et al. Should bleeding tendency deter abdominal paracentesis? Dig Liv Dis 2005;37:946–51.CrossRefGoogle ScholarPubMed
Thomsen, TW, Shaffer, RW, White, B, Setnik, GS. Paracentesis. N Engl J Med 2006;355:e21.CrossRefGoogle ScholarPubMed
Habeeb, KS, Herrera, JL. Management of ascites. Paracentesis as a Guide. Postgrad Med 1997;101:191–200.CrossRefGoogle ScholarPubMed
Runyon, BA, Montano, AA, Akriviadis, EA, Antillon, MR, Irving, MA, McHutchison, JG. The serum-ascites albumin gradient is superior to the exudates-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992;117:215–20.CrossRefGoogle ScholarPubMed
Llach, J, Rimola, A, Navasa, M, et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992;16:724–27.CrossRefGoogle ScholarPubMed
Soriano, G, Guarner, C, Teixido, M, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477–81.CrossRefGoogle ScholarPubMed
Runyon, BA, Hoefs, JC, Morgan, TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988;8:1104–9.CrossRefGoogle ScholarPubMed
Stiehm, AJ, Mendler, MH, Runyon, BA. Detection of diuretic resistance or diuretic sensitivity by the spot urine Na/K ratio in 729 specimens from cirrhotics with ascites: approximately 80% accuracy as compared to 24 hour urine Na excretion. Hepatology 2002:36:222A [abstract]Google Scholar
Perez-Ayuso, RM, Arroyo, V, Plans, R, Gaya, J, Bory, F, Rimola, A, Rivea, F, et al. Randomized comparative study of efficacy of furosemide vs. spironolactone in nonazotemic cirrhosis with ascites. Gastroenterology 1983;84:961–8.Google Scholar
Santos, J, Planas, R, Pardo, A, Durandez, R, Cabre, E, Mrillas, RM, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003;39:187–92.CrossRefGoogle ScholarPubMed
Runyon, BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004;39:841–56.CrossRefGoogle ScholarPubMed
Fitzgerald, GA, Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433–42.CrossRefGoogle ScholarPubMed
Claria, J, Kent, JD, Lopez-Parra, M, Escolar, G, Ruiz, delArbol, L, Gines, P, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 2005;41:579–87.CrossRefGoogle ScholarPubMed
Gines, P, Tito, L, Arroyo, V, Planas, R, Viver, J, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493–501.CrossRefGoogle ScholarPubMed
Sanyal, A, Genning, C, Reddy, KR, Wong, F, Kowdley, KV, Benner, K, et al. The North American study for the treatment of refractory ascites. Gastroenterology 2003;124:634–41.CrossRefGoogle ScholarPubMed
Gines, P, Arroyo, V, Vargas, V, Plans, R, Casafont, F, Panes, J, Hoyos, M, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991;325:829–35.CrossRefGoogle ScholarPubMed
Moore, KP, Aithal, GP. Guidelines on the management of ascites in cirrhosis. Gut 2006;55:1–12.CrossRefGoogle ScholarPubMed
Felisart, J, Rimola, A, Arroyo, V, Perez-Ayuso, RM, Quintero, E, Gines, P, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985;5:457–62.CrossRefGoogle ScholarPubMed
Runyon, BA, McHutchison, JG, Antillon, MR, et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis: a randomized controlled study of 100 patients. Gastroenterology 1991;100:1737–42.CrossRefGoogle ScholarPubMed
Llovet, JM, Rodriguez-Iglesias, P, Moitinho, E, Planas, R, Bataller, R, Navasa, M, et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol 1997;26:88–95.CrossRefGoogle ScholarPubMed
Campillo, B, Richardet, JP, Kheo, T, Dupeyron, C. Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. Clin Infect Dis 2002;35:1–10.CrossRefGoogle Scholar
Sort, P, Navasa, M, Arroyo, V, Aldeguer, X, Planas, R, Ruiz, delArbol, L, et al. Effects of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403–9.CrossRefGoogle Scholar
Gines, P, Rimola, A, Planas, R, Vargas, V, Marco, F, Almela, M. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716–24.CrossRefGoogle ScholarPubMed
Bauer, TM. Follo, A, Navasa, M, Vila, J, Plans, R, Clemente, G, et al. Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. Dig Dis Sci 2002;47:1356–61.CrossRefGoogle ScholarPubMed
Arroyo, V, Gines, P, Berges, A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164–76.CrossRefGoogle ScholarPubMed
Gines, A, Escorsell, A, Gines, P, et al. Incidence, predictive factors and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 1993;105:229–36.CrossRefGoogle ScholarPubMed
Cardenas, A.Hepatorenal syndrome: A dreaded complication of end-stage liver disease. Am J Gastroenterol 2005;100:460–7.CrossRefGoogle ScholarPubMed
Ortega, R, Gines, P, Uriz, J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Results of a prospective, non-randomized study. Hepatology 2002;36:941–8.CrossRefGoogle Scholar
Angeli, P, Volpin, R, Gerunda, G, Craighero, R, Roner, P, Merenda, R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690–7.CrossRefGoogle ScholarPubMed
Wong, F, Pantea, L, Sniderman, K. Midodrine, octreotide, albumin and TIPS in selected patiens with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55–64.CrossRefGoogle Scholar
Butterworth, RF. The neurobiology of hepatic encephalopathy. Semin Liv Dis 1996;16:235–44.CrossRefGoogle ScholarPubMed
Blei, AT, Cordoba, J. Hepatic Encephalopathy. Am J Gastroenterol 2001;96:1968–76.CrossRefGoogle ScholarPubMed
Uribe, M, Campollo, A, Vargas, F, et al. Acidifying enemas (lactitol and lactose) vs. non-acidifiying enemas (tap water) to treat acute portal-systemic encephalopathy. A double-blind randomized clinical trial. Hepatology 1987;7:639–43.CrossRefGoogle ScholarPubMed
Loft, S, Sonne, J, Dossing, M, Andreasen, PB. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 1987;22:117–23.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×